Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Investigative Medicine Division aims to rapidly translate innovative science into patient benefit across a range of disease areas. From molecular biology and target discovery, through to interventional medicine and informing policy, we bring together researchers in a diverse range of specialties including acute stroke, dementia and immunology.

© Martin Phelps

Specific research groups include:

The Acute Multidisciplinary Imaging and Interventional Centre (AMIIC), which aims to deliver cutting edge research that will improve the assessment and diagnosis of patients with acute coronary syndromes and stroke and facilitate the development of new treatments.

The Buchan Group's Laboratory of Cerebral Ischemia is a pre-clinical research group aiming to uncover mechanisms of cell death in stroke, and develop novel strategies to reduce this. Group members have also developed in-vitro models for neurological diseases, and work on neuroimmunology

The MRC Translational Immune Discovery Unit (TIDU) aims to uncover the molecular pathways driving immune-mediated diseases – researchers in the unit develop and harness new technologies to map the causes and molecular drivers of a series of inflammatory disorders in order to develop better ways to treat them.

Professor Alison Simmons is the Head of Investigative Medicine.

Researchers have major collaborations with the MRC, the Wellcome Trust, CRUK and the NIHR, as well as cross-departmental collaborations such as Human Iron Research at Oxford (HIRO).